Opinion|Videos|January 24, 2025
Strategies for Equitable Access in Hidradenitis Suppurativa
Author(s)Hadar Lev-Tov, MD
Panelist discusses how rapid access clinics could revolutionize HS patient care by providing swift, comprehensive diagnostic pathways, integrating multidisciplinary expertise, and enabling early intervention. Strategies for equitable access include telemedicine, mobile diagnostic units, community health worker training, sliding-scale pricing, and partnerships with local health care providers to overcome geographical and economic barriers in underserved regions.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- In what ways could rapid access clinics serve as a model for early diagnosis and coordinated care for HS patients?
- What strategies can be employed to ensure equitable access to diagnostic services for patients in underserved areas?
Advertisement
Related to this article
Michael Mina, MD, PhD, explains which adverse events drove VYD2311's edge vs an mRNA COVID-19 vaccine and who may benefit most.
The FDA approves atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III dMMR colon cancer based on the ATOMIC trial.
Michael Mina, MD, PhD, explains Invivyd's accelerated approval path for VYD2311 and how it could change the timing of COVID-19 protection.
Biomarker-driven care is advancing in mantle cell lymphoma, though cost and infrastructure limit access in community oncology, according to a review.
Fibrosis stage, not MASH resolution, best predicts mortality, which should shape trial end points, says Georgetown's Zobair Younossi, MD, MPH.
Remibrutinib (Rhapsido; Novartis) is the only treatment with approved uses in both chronic spontaneous urticaria and symptomatic dermographism.
Lean MASLD shows milder histology than overweight and obese MASLD but similar mortality and event risk, with fibrosis tied to prognosis.
Hepatitis reports after vaccination were more often serious in children, but the data lack dose counts and cannot show vaccine-specific risk.
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know if Retatrutide Is Classified as a Biologic
2
FDA Approves First Symptomatic Dermographism Treatment
3
Sacral Neuromodulation Still Seen as OAB Gold Standard in Review
4
Predoc and Nebraska Cancer Specialists: Not Letting the Fax Be the Fumble
5